Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
Related Questions
Under what circumstances would you offer PMRT in a patient with DCIS?
Would you offer partial breast radiation for bilateral DCIS?
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
When treating early stage breast cancer with adjuvant RT, what risk factors would lead you to include the level 1 and 2 axilla in patients with pN0(i+) disease?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
Would you recommend PMRT for multifocal IDC with extensive LVI and 1 SLN with ITCs?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
When do you consider the addition of concurrent pembrolizumab to breast irradiation?
Would you feel comfortable doing high tangents with ultra-hypofractionation?
